Mohammad AskarPublic working copy · medical review pending

Neuro-ophthalmology and relevant retinal diseases · 046

Retinal disease in neuro-ophthalmology

Recognise retinal mimics of optic neuropathy and investigate possible systemic disease.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

A normal early fundus does not exclude retinal dysfunction; combine OCT, ERG and visual fields.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Start with symptoms and signs

Pain, visual loss, photopsias and metamorphopsias are reported symptoms; RAPD, optic-disc swelling and retinal vascular attenuation are examination signs. Reported visual loss can be measured, so subjective does not mean impossible to assess objectively. These uncommon retinal disorders may be overlooked when the early fundus looks normal. Their recognition can uncover systemic disease, including an occult tumour, without guaranteeing a particular prognosis. 1

Document onset, laterality, acuity, colour vision, pupils, fields and fundus. OCT localises structural change; full-field ERG assesses widespread rod/cone and postreceptoral dysfunction. Interpret the waveform, imaging and fields together rather than diagnosing AIR from a single symptom or serum test. Inherited, toxic, inflammatory and neurological disease remain competing explanations. 1 2

Start with symptoms and signs
PhenomenonDescriptionInterpretation
PhotopsiaFlashes, stars or flickering without an external light source; visual snow needs separate characterisation.Retinal or optic-nerve causes are possible; visual snow also has central causes.
MetamorphopsiaStraight lines look wavy; perceived size (micropsia/macropsia) or distance may change.Suggests macular dysfunction, requiring examination.
DyschromatopsiaColour desaturation through profound colour loss/achromatopsia.Can occur in retinal and optic-nerve disorders.

02Identify an autoimmune retinal phenotype

Paraneoplastic AIR includes cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR). Tumour-directed immune responses may cross-react with retinal proteins. Nonparaneoplastic AIR (npAIR) is considered only after appropriate exclusion of malignancy and alternative retinal disease; lupus or thyroid autoimmunity may coexist but does not establish the diagnosis. The reported predominance in middle-aged women is a clinical tendency, not an eligibility rule. 1

Antiretinal antibodies support a compatible phenotype but are not sufficient evidence of AIR or cancer. In a small selected cross-sectional study, 13 of 14 people without AIR had a positive panel; this warns against indiscriminate testing and does not estimate every laboratory assay’s accuracy. Recoverin and alpha-enolase have different associations and cannot be treated as interchangeable markers. 3

03Recognise CAR and assess for cancer

CAR can cause rapidly progressive bilateral loss from photoreceptor dysfunction. Small-cell lung carcinoma is a prominent association in the export; breast, uterine, cervical and colorectal cancers are also listed. Visual symptoms may precede tumour detection by months or years. Early fundus appearances may be normal; later optic-disc pallor, vascular attenuation and RPE atrophy can develop. 1

OCT may show ellipsoid-zone disruption or loss; ERG a- and b-waves may be markedly reduced or absent, with a midperipheral ring scotoma on perimetry. Anti-recoverin or anti-alpha-enolase findings require clinical interpretation. Arrange a coordinated malignancy assessment tailored to history and risk; no single PET examination is a universal gold standard for all suspected AIR. 1 2

04Recognise a negative ERG pattern in MAR

MAR may accompany cutaneous melanoma, reveal occult disease or appear with recurrence after prior treatment. Abrupt night blindness and flickering photopsias are important clues. Antibodies against TRPM1 can impair ON bipolar-cell signalling. A relatively preserved a-wave with a markedly depressed b-wave produces an electronegative ERG; this localises dysfunction but is not specific to melanoma. 1 4

The fundus is often unremarkable and fields may show general depression. The export contrasts inner-retinal OCT abnormalities with an intact outer ellipsoid zone; this is a teaching pattern, not a required or sufficiently specific imaging criterion. Coordinate melanoma investigation or staging with oncology; PET may be selected when indicated rather than being mandatory for every presentation. 1

Recognise a negative ERG pattern in MAR
FeatureCARMAR
Cancer associationSmall-cell lung, breast and other carcinomas.Cutaneous melanoma, including occult or recurrent disease.
Main cellular targetPhotoreceptors in the outer retina.ON bipolar-cell signalling in the inner retina.
Leading symptomsProgressive visual loss and photopsias.Often acute night blindness and flickering.
OCT patternEllipsoid-zone damage.Outer zone may be preserved; inner-layer changes are not obligatory or specific.
ERG patternReduced a- and b-waves.Depressed b-wave with relatively preserved a-wave; not melanoma-specific.
Typical field descriptionMidperipheral ring scotoma.General depression; patterns vary in both entities.

05Discuss limited treatment evidence openly

Corticosteroids, IVIG, plasma exchange and other immunosuppressants have been tried in AIR. The export’s statement of no significant benefit must not be read as proof that every treatment is ineffective. No universally effective regimen is established; evidence is limited and paraneoplastic management includes treatment of the underlying cancer. Structural damage may be irreversible. 1 5

npAIR may present with photopsias, scotomas and night blindness and abnormal OCT/ERG after a negative appropriate cancer assessment. Reconsider alternative diagnoses and reassess cancer risk when the clinical course changes. Some patients improve with immunomodulation, but better vision than in CAR/MAR is not guaranteed. A 17-expert Delphi process supported selected immunosuppressive approaches while explicitly calling for stronger treatment evidence; consensus is not a randomised efficacy trial. 1 5

06Separate blind-spot enlargement from papilloedema

Acute idiopathic blind-spot enlargement syndrome (AIBSE/AIBSES) is usually unilateral, often in young or middle-aged women, with photopsias and a grey patch corresponding to the enlarged blind spot. The defect may persist. Peripapillary outer-retinal OCT abnormalities can be more informative than a subtle or normal fundus; slight disc swelling is possible. Overlap with MEWDS is described, and transient white dots need not be visible. 1 6

IIH more typically produces bilateral papilloedema, headache and pulsatile tinnitus. These tendencies cannot by themselves exclude raised intracranial pressure, particularly with worrying neurological symptoms. Glaucoma may also alter the field but requires assessment of optic-nerve excavation and progression. Do not equate every enlarged blind spot with one of these diagnoses. 1 6

07Consider inherited retinal dysfunction

Cone dystrophy causes difficulty in bright light, photophobia and progressive dyschromatopsia and can be mislabelled optic neuropathy. Severe central impairment may meet a jurisdiction’s legal-blindness definition, but this is not an inevitable outcome of every cone dystrophy. Rod-predominant disease such as retinitis pigmentosa commonly causes night blindness, progressive peripheral field constriction and pigmentary changes; later cone involvement can compromise central vision, with variable course. 1

Use the symptom pattern, OCT, fields and electrophysiology to distinguish retinal and optic-nerve disease. Where inherited disease is plausible, seek specialist phenotyping and appropriate genetic counselling/testing. When AIR remains plausible, coordinate systemic investigation and follow-up rather than relying on a normal fundus, a positive antibody panel or a single negative cancer scan. 1 2

What is the main diagnostic lesson?

Normal early fundus findings do not exclude retinal dysfunction. Combine symptoms, OCT, fields and ERG, interpret antibodies cautiously and investigate systemic disease when indicated.

When is assessment urgent?

Sudden visual loss, new flashes with floaters or a curtain, or disc swelling with severe headache or neurological symptoms requires urgent assessment. Progressive unexplained night blindness also needs timely specialist evaluation.

References and access status

  1. 1
    Immutable original export; attributed to Dr. Ayman Oqla Suleiman

    Complete export read; recording, attribution and institutional role not independently verified.

  2. 2
    AAO: Guidelines for the Diagnosis, Management, and Study of Autoimmune Retinopathy (2025)

    Indexed diagnostic excerpts read; direct page returned 403. No complete full-text or supplement access claimed.

  3. 3
    Clinical Utility of Antiretinal Antibody Testing (2021)

    Indexed PubMed abstract read; small selected cross-sectional sample, not universal assay validation. Direct page did not expose the abstract.

  4. 4
    Dhingra et al.: Autoantibodies in melanoma-associated retinopathy target TRPM1 (2011)

    Indexed mechanistic excerpts inspected; no whole-text access or clinical treatment efficacy inferred.

  5. 5
    Fox et al.: Modified Delphi consensus on nonparaneoplastic AIR (2016)

    PubMed abstract read; 17-expert consensus, not a randomised treatment trial.

  6. 6
    Zimmermann et al.: AIBSES—New Perspectives in the OCT Era (2022)

    Indexed complete abstract read; three-patient case series, not comparative efficacy evidence. Direct PubMed page did not expose the abstract.

Original lecture link